Potential Cardioprotective Effects of Sumac Capsule in Patients With Hyperlipidemia: A Triple-Blind Randomized, Placebo-Controlled Crossover Trial

Asgary, Sedigheh. and Salehizadeh, Leila. and Keshvari, Mahtab. and Taheri, Marzieh. and Spence, Nicholas D. and Farvid, Maryam.s. and Rafieian-Kopaei, Mahmoud. and Sarrafzadegan, Nizal. (2018) Potential Cardioprotective Effects of Sumac Capsule in Patients With Hyperlipidemia: A Triple-Blind Randomized, Placebo-Controlled Crossover Trial. Journal of the American College of Nutrition, 37 (4).

Full text not available from this repository.

Abstract

Objective: Alternative medicine and herbal drugs have been taken into account for managing cardiovascular risk factors. Sumac (Rhus coriaria L.) is rich in biologically active ingredients known to improve cardiovascular health. We investigated the effect of sumac on systolic (SBP) and diastolic (DBP) blood pressure, flow-mediated dilation (FMD), body mass index (BMI), and serum concentrations of lipids and fasting blood sugar (FBS) in participants with hyperlipidemia in a triple-blind randomized placebo- controlled crossover trial. Methods: Thirty adults with dyslipidemia (mild to moderate elevation of plasma total cholesterol and/or triglycerides [TG; total cholesterol ≥ 6.0 mmol/L or TG ≥ 1.7 mmol/L and TG ≤ 5.0 mmol/L]) were assigned randomly to a sumac or a placebo group. Participants in the sumac group received sumac capsules (500 mg/twice daily) for the first 4 weeks, followed by 2 weeks’ washout period; the patients were then switched to a 4-week interval and received placebo for 4 weeks in the second period. The placebo group received these treatments in reverse order. FMD, BMI, SBP, DBP, lipids, and FBS were measured at baseline and after each period. Results: Differences between placebo group and sumac group (placebo-sumac) were significantly decreased for BMI (0.21 ± 0.075 kg/m2), SBP (1.87 ± 0.83 mm Hg), DBP (1.32 ± 0.46 mm Hg), and total cholesterol (14.42 ± 4.95 mmol/L) and significantly increased for FMD (−0.23% ± 0.065%). Plasma level of TG did not change significantly across the treatment. Conclusion: Sumac consumption may decrease cardiovascular risk factors in persons with mild to moderate hyperlipidemia. © 2018 American College of Nutrition.

Item Type: Article
Uncontrolled Keywords: blood pressure,Crossover trial,dyslipidemia,flow-mediated dilation,Rhussumac
Subjects: WG Cardiovascular System
QV pharmacology > QV 752 Pharmacognosy
Divisions: Reserach Vice-Chancellar Department > Medical Plants Research Center
Depositing User: zahra bagheri .
Date Deposited: 29 Aug 2018 06:27
Last Modified: 29 Aug 2018 06:27
URI: http://eprints.skums.ac.ir/id/eprint/7047

Actions (login required)

View Item View Item